BREAKING
NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago
ADVERTISEMENT
Market News

Agilysys Projects 29% Subscription Growth in Raised Outlook

Agilysys, Inc. (Nasdaq: AGYS) has updated its financial guidance for the full fiscal year 2026, raising revenue expectations while maintaining targets for operational profitability. Equity Analyst Commentary Equity Analyst Commentary Market analysts have noted the divergence between top-line growth and quarterly earnings. While revenue exceeded targets, the adjusted EPS of $0.42 missed the estimated $0.46. […]

January 26, 2026 1 min read

Agilysys, Inc. (Nasdaq: AGYS) has updated its financial guidance for the full fiscal year 2026, raising revenue expectations while maintaining targets for operational profitability. Equity Analyst Commentary Equity Analyst Commentary Market analysts have noted the divergence between top-line growth and quarterly earnings. While revenue exceeded targets, the adjusted EPS of $0.42 missed the estimated $0.46. […]

Agilysys, Inc. (Nasdaq: AGYS) has updated its financial guidance for the full fiscal year 2026, raising revenue expectations while maintaining targets for operational profitability.

Equity Analyst Commentary

Equity Analyst Commentary Market analysts have noted the divergence between top-line growth and quarterly earnings. While revenue exceeded targets, the adjusted EPS of $0.42 missed the estimated $0.46. Firms including Needham and Oppenheimer maintain positive ratings, citing long-term growth in subscription bookings. Conversely, Zacks Equity Research maintains a Hold ranking, highlighting the impact of increased operational expenses on near-term margins.

Guidance & Outlook

The updated guidance for fiscal year 2026 includes:

  • Total Revenue: Raised to a range of $315 million to $318 million.
  • Subscription Revenue: Projected growth of approximately 29% year-over-year.
  • Profitability: Adjusted EBITDA is expected to remain at approximately 20% of total revenue.

Performance Summary

Agilysys shares moved 2.4% lower today. Latest results show revenue of $79.3 million, marking a 16.5% year-over-year increase. Subscription segments showed expansion, while net profit decreased slightly to $3.9 million. The company maintains an upward revenue revision for the full year.

ADVERTISEMENT